 | Up a level |
2018
Arshad, U., Taubert, M., Kurlbaum, M., Frechen, S., Herterich, S., Megerle, F., Hamacher, S., Fassnacht, M., Fuhr, U. and Kroiss, M. (2018). Enzyme autoinduction by mitotane supported by population pharmacokinetic modeling in a large cohort of adrenocortical carcinoma patients. Eur. J. Endocrinol., 179 (5). S. 287 - 298. BRISTOL: BIOSCIENTIFICA LTD. ISSN 1479-683X
2015
Dahlinger, D., Frechen, S., Aslan, S. and Fuhr, U. (2015). In Vitro Assessment of Direct and Time-Dependent Inhibitory Effects on Major Human Cytochrome P450 Enzymes by Spasmolytics. Naunyn-Schmiedebergs Arch. Pharmacol., 388. S. S49 - 1. NEW YORK: SPRINGER. ISSN 1432-1912
Dahlinger, D., Frechen, S., Aslan, S. and Fuhr, U. (2015). In Vitro Assessment of Direct and Time-Dependent Inhibitory Effects on Major Human Cytochrome P450 Enzymes by Spasmolytics. Naunyn-Schmiedebergs Arch. Pharmacol., 388. S. S49 - 1. NEW YORK: SPRINGER. ISSN 1432-1912
Frechen, S., Suleiman, A. A., Sigaroudi, Mohammad Nejad A., Wachall, B. and Fuhr, U. (2015). Population Pharmacokinetic and Pharmacodynamic Modeling of Epinephrine administered using a Mobile Inhaler. Naunyn-Schmiedebergs Arch. Pharmacol., 388. S. S51 - 1. NEW YORK: SPRINGER. ISSN 1432-1912
Frechen, S., Suleiman, A. A., Sigaroudi, Mohammad Nejad A., Wachall, B. and Fuhr, U. (2015). Population Pharmacokinetic and Pharmacodynamic Modeling of Epinephrine administered using a Mobile Inhaler. Naunyn-Schmiedebergs Arch. Pharmacol., 388. S. S51 - 1. NEW YORK: SPRINGER. ISSN 1432-1912
2014
Nogova, L., Mattonet, C., Gardizi, M., Scheffler, M., Bos, M., Woempner, C., Toepelt, K., Heukamp, L., Suleiman, A., Frechen, S., Soergel, F., Fuhr, U., Schnell, R., Katay, I., Behringer, D., Geist, T., Kaminski, B., Eichstaedt, M., Tummes, D., Buettner, R. and Wolf, J. (2014). SORAVE: Sorafenib and everolimus for patients with solid tumors and with KRAS mutated NSCLC - results of a phase I study. Oncol. Res. Treat., 37. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262